Waltham, MA-based NKT Therapeutics, a developer of drugs targeting lesser-known immune cells potentially linked to a number of major illnesses, raised $4 million in an equity round from three unnamed investors, according to an SEC filing. Last year, the company raised an $8 million Series A round led by SV Life Sciences and MedImmune Ventures. Ryan wrote about the company’s plans to develop drugs that stimulate white blood cells called natural killer T cells as part of a broader immune response to conditions like asthma and cancer.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
